PRIMARY IGA NEPHROPATHY
Clinical trials for PRIMARY IGA NEPHROPATHY explained in plain language.
Never miss a new study
Get alerted when new PRIMARY IGA NEPHROPATHY trials appear
Sign up with your email to follow new studies for PRIMARY IGA NEPHROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kidney disease: HRS-5965 aims to slow IgA nephropathy
Disease control Not yet recruitingThis study tests the long-term safety of an experimental drug, HRS-5965, in 380 adults with primary IgA nephropathy, a kidney disease. The goal is to see if the drug can reduce protein in the urine and help preserve kidney function over time. Participants must have completed a pr…
Matched conditions: PRIMARY IGA NEPHROPATHY
Phase: PHASE2 • Sponsor: Chengdu Suncadia Medicine Co., Ltd. • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New shot aims to slow silent kidney damage
Disease control Not yet recruitingThis study is testing whether an investigational injection called SHR-2173 can help control IgA nephropathy, a kidney disease where protein leaks into the urine. About 84 adult patients will receive either the real injection or a placebo (dummy shot) for 48 weeks to see if it saf…
Matched conditions: PRIMARY IGA NEPHROPATHY
Phase: PHASE2 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Apr 23, 2026 12:44 UTC